이식 진단 시장 규모, 점유율과 동향 분석 리포트 : 검사별, 제품별, 용도별, 이식 부위별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Transplant Diagnostics Market Summary

The global transplant diagnostics market size was estimated at USD 6.39 billion in 2024 and is expected to reach USD 12.15 billion in 2033, growing at a CAGR of 7.45% from 2025 to 2033. The rising prevalence of genetic disorders, technological advancements in genetic testing, and growing awareness and demand for personalized medicine are boosting the market growth.

For instance, in October 2025, UBC enzyme technology introduced the first human test toward universal donor organs for transplantation. It has developed enzymes that successfully convert a kidney to universal type O for transplant, marking a significant step toward faster, more compatible organ donations. Further, the results show that the kidney functioned normally for two days without evidence of hyperacute rejection. This quick immune reaction can destroy an incompatible organ in minutes. By the third day, some blood-type markers resurfaced, causing a moderate response. Still, the damage was significantly less severe than in a usual mismatch, and researchers noticed signals that the body was starting to tolerate the organ.

Furthermore, the aging population, the prevalence of chronic disease, and advances in transplantation techniques are all driving market growth. For example, in October 2025, the World Health Organization claimed that in 2020, individuals aged 60 and older outnumbered children under five. Between 2015 and 2050, the worldwide population over 60 will almost double, from 12% to 22%. Furthermore, by 2050, 80% of older people will reside in low- and middle-income countries. The pace of population ageing is much faster than in the past. As chronic diseases such as heart failure, kidney disease, and liver disorders continue to rise, the need for organ transplantation as a life-saving treatment is also increasing. This rise in transplant procedures highlights the importance of accurate and advanced diagnostic tools to ensure donor-recipient compatibility, reduce the risk of organ rejection, and improve transplantation success rates.

Global Transplant Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global transplant diagnostics market report based on test, product, application, transplant area, end-use, and region:

• Test Outlook (Revenue, USD Million, 2021 - 2033)
  • Molecular Assays
• PCR-based Molecular Assays
• Real-time PCR
• Sequence-based Primer-PCR
• Sequence-specific Oligonucleotide-PCR
• Other PCR-based Molecular Assays
  • Sequencing-based Molecular Assays
• Sanger Sequencing
• Next Generation Sequencing
• Other Sequencing-based Molecular Assays
  • Non-molecular Assays
• Serological Assays
• Mixed Lymphocyte Culture Assays
• Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Reagents & Consumables
  • Instruments
  • Software and Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostic Application
• Infectious Disease Testing
• Histocompatibility Testing
• Blood Profiling
  • Research Application
• Transplant Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Solid Area Transplantation
• Kidney Transplantation
• Liver Transplantation
• Heart Transplantation
• Lung Transplantation
• Pancreas Transplantation
• Other Organs Transplantation
  • Stem Cell Transplantation
  • Soft Tissue Transplantation
  • Bone Marrow Transplantation
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Transplant Centers
  • Research and Academic Institutes
  • Independent Reference Laboratories
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
• U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Transplant Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Test
    • 1.1.1.2. Product Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. Transplant Area Segment
    • 1.1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Transplant Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Test
• 2.3. Product Snapshot
• 2.4. Application Snapshot
• 2.5. Transplant Area Snapshot
• 2.6. End Use Snapshot
• 2.7. Competitive Landscape Snapshot

Chapter 3. Transplant Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising prevalence of genetic disorders
  • 3.4.2. Technological advancements in genetic testing
  • 3.4.3. Growing awareness and demand for personalized medicine
• 3.5. Market Restraint Analysis
  • 3.5.1. Limited implementation of public health screening
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Transplant Diagnostics Market: Test Estimates & Trend Analysis

• 4.1. Transplant Diagnostics Market: Test Movement Analysis
• 4.2. Molecular Assays
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. PCR-based Molecular Assays
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Real-time PCR
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Sequence-based Primer-PCR
    • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.5. Sequence-specific Oligonucleotide-PCR
  • 4.2.6. Other PCR-based Molecular Assays
    • 4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Sequencing-based Molecular Assays
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Sanger Sequencing
    • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Next Generation Sequencing
    • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Other Sequencing-based Molecular Assays
    • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Non-molecular Assays
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Serological Assays
    • 4.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Mixed Lymphocyte Culture Assays
    • 4.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Transplant Diagnostics Market: Product Estimates & Trend Analysis

• 5.1. Transplant Diagnostics Market: Product Movement Analysis
• 5.2. Reagents & Consumables
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Instruments
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Software and Services
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Transplant Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Transplant Diagnostics Market: Application Movement Analysis
• 6.2. Diagnostic Application
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.2. Infectious Disease Testing
    • 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.3. Histocompatibility Testing
    • 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.4. Blood Profiling
• 6.3. Research Application
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Transplant Diagnostics Market: Transplant Area Estimates & Trend Analysis

• 7.1. Transplant Diagnostics Market: Transplant Area Movement Analysis
• 7.2. Solid Area Transplantation
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.2. Kidney Transplantation
    • 7.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.3. Liver Transplantation
    • 7.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.4. Heart Transplantation
    • 7.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.5. Lung Transplantation
    • 7.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.6. Pancreas Transplantation
    • 7.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.7. Other Organs Transplantation
    • 7.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Stem Cell Transplantation
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Soft Tissue Transplantation
    • 7.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Bone Marrow Transplantation
    • 7.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Transplant Diagnostics Market: End Use Estimates & Trend Analysis

• 8.1. Transplant Diagnostics Market: End Use Movement Analysis
• 8.2. Hospitals and Transplant Centers
  • 8.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.3. Research and Academic Institutes
  • 8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Independent Reference Laboratories
  • 8.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Transplant Diagnostics Market: Regional Business Analysis

• 9.1. Regional Market Snapshot
• 9.2. North America
  • 9.2.1. North America Transplant Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. U.S. Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.2.2.2. Key Country Dynamics
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. Reimbursement Scenario
    • 9.2.2.5. Competitive Scenario
  • 9.2.3. Canada
    • 9.2.3.1. Canada Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.2.3.2. Key Country Dynamics
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Reimbursement Scenario
    • 9.2.3.5. Competitive Scenario
  • 9.2.4. Mexico
    • 9.2.4.1. Mexico Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.2.4.2. Key Country Dynamics
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Reimbursement Scenario
    • 9.2.4.5. Competitive Scenario
• 9.3. Europe
  • 9.3.1. Europe Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. UK Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.2.2. Key Country Dynamics
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. Reimbursement Scenario
    • 9.3.2.5. Competitive Scenario
  • 9.3.3. Germany
    • 9.3.3.1. Germany Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.3.2. Key Country Dynamics
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Reimbursement Scenario
    • 9.3.3.5. Competitive Scenario
  • 9.3.4. Spain
    • 9.3.4.1. Spain Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.4.2. Key Country Dynamics
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Reimbursement Scenario
    • 9.3.4.5. Competitive Scenario
  • 9.3.5. France
    • 9.3.5.1. France Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.5.2. Key Country Dynamics
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Reimbursement Scenario
    • 9.3.5.5. Competitive Scenario
  • 9.3.6. Italy
    • 9.3.6.1. Italy Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.6.2. Key Country Dynamics
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Reimbursement Scenario
    • 9.3.6.5. Competitive Scenario
  • 9.3.7. Denmark
    • 9.3.7.1. Denmark Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.7.2. Key Country Dynamics
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Reimbursement Scenario
    • 9.3.7.5. Competitive Scenario
  • 9.3.8. Sweden
    • 9.3.8.1. Sweden Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.8.2. Key Country Dynamics
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Reimbursement Scenario
    • 9.3.8.5. Competitive Scenario
  • 9.3.9. Norway
    • 9.3.9.1. Norway Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.3.9.2. Key Country Dynamics
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Reimbursement Scenario
    • 9.3.9.5. Competitive Scenario
• 9.4. Asia Pacific
  • 9.4.1. Asia-Pacific Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Japan Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.4.2.2. Key Country Dynamics
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Scenario
    • 9.4.2.5. Competitive Scenario
  • 9.4.3. China
    • 9.4.3.1. China Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.4.3.2. Key Country Dynamics
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Scenario
    • 9.4.3.5. Competitive Scenario
  • 9.4.4. India
    • 9.4.4.1. India Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.4.4.2. Key Country Dynamics
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Scenario
    • 9.4.4.5. Competitive Scenario
  • 9.4.5. South Korea
    • 9.4.5.1. South Korea Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.4.5.2. Key Country Dynamics
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Reimbursement Scenario
    • 9.4.5.5. Competitive Scenario
  • 9.4.6. Thailand
    • 9.4.6.1. Thailand Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.4.6.2. Key Country Dynamics
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Reimbursement Scenario
    • 9.4.6.5. Competitive Scenario
  • 9.4.7. Australia
    • 9.4.7.1. Australia Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.4.7.2. Key Country Dynamics
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Reimbursement Scenario
    • 9.4.7.5. Competitive Scenario
• 9.5. Latin America
  • 9.5.1. Latin America Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Brazil Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.5.2.2. Key Country Dynamics
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Scenario
    • 9.5.2.5. Competitive Scenario
  • 9.5.3. Argentina
    • 9.5.3.1. Argentina Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.5.3.2. Key Country Dynamics
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Scenario
    • 9.5.3.5. Competitive Scenario
• 9.6. MEA
  • 9.6.1. MEA Transplant Diagnostics Market, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. South Africa Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.6.2.2. Key Country Dynamics
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Scenario
    • 9.6.2.5. Competitive Scenario
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Saudi Arabia Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.6.3.2. Key Country Dynamics
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Scenario
    • 9.6.3.5. Competitive Scenario
  • 9.6.4. UAE
    • 9.6.4.1. UAE Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.6.4.2. Key Country Dynamics
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Scenario
    • 9.6.4.5. Competitive Scenario
  • 9.6.5. Kuwait
    • 9.6.5.1. Kuwait Transplant Diagnostics Market, 2021 - 2033 (USD Million)
    • 9.6.5.2. Key Country Dynamics
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Scenario
    • 9.6.5.5. Competitive Scenario

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
  • 10.2.1. New product launch
  • 10.2.2. Partnerships
  • 10.2.3. Acquisition
  • 10.2.4. Collaboration
  • 10.2.5. Funding
• 10.3. Key Company Market Share Analysis, 2024
• 10.4. Company Heat Map Analysis
• 10.5. Company Profiles
  • 10.5.1. Thermo Fisher Scientific, Inc.
    • 10.5.1.1. Company Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Illumina, Inc.
    • 10.5.2.1. Company Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. F. Hoffmann La-Roche Ltd
    • 10.5.3.1. Company Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Abbott
    • 10.5.4.1. Company Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. QIAGEN
    • 10.5.5.1. Company Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Bruker
    • 10.5.6.1. Company Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. BD (Becton, Dickinson and Company)
    • 10.5.7.1. Company Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Werfen (Immucor, Inc.)
    • 10.5.8.1. Company Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Bio-Rad Laboratories, Inc.
    • 10.5.9.1. Company Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Omixon Inc.
    • 10.5.10.1. Company Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives